
Age
2 - 17
Check your eligibility now & get in touch with a study center
CHECK ELIGIBILITYThe study will include a screening period of up to 60 days (Day -60 to -1), a primary analysis treatment period (Day 1 to Week 52), a long-term treatment period (Week 53 to Week 104), and an extension period continuing up to Week 364 (for patients who continue to demonstrate the clinical benefit from eliglustat monotherapy at Week 104). After study completion, patients will be encouraged to enroll in the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
You can use content blocks to arrange your articles, large texts, instructions. Combine these blocks with media blocks to add illustrations and video tutorials. You can use various content blocks to work with your text. Add quotations, lists, buttons. Select your text to change its formatting or add links. You can use various content blocks to work with your text. Add quotations, lists, buttons. Select your text to change its formatting or add links.

Take up this questionnaire to help us determine if you have symptoms that are common to this clinical study. If you have the common symptoms, you may be eligible to take part in the study.

2 - 17

All

NCT03485677

3

Recruiting Now

Gaucher Disease

A short sentence to introduce what to expect in the about condition section
Learn more
A short sentence to introduce what to expect in the about condition section
Learn more
A short sentence to introduce what to expect in the about condition section
Learn moreYou would receive etanercept (Enbrel) twice a week for 12 weeks and then once a week for 12 weeks. Etanercept, as well as study related medical care, is provided at no cost.
Study participation involves approximately 8 visits to your local study center over 6 to 7 months.
There would also be a follow-up telephone call 30days after completing the study. No visits are required after participation is complete.